53 related articles for article (PubMed ID: 38581544)
1. Imbalance of the von Willebrand Factor - ADAMTS-13 axis in patients with retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S).
Braune M; Metelmann M; de Fallois J; Pfrepper C; Barrantes-Freer A; Hiller GGR; Unger S; Seelow E; Halbritter J; Pelz JO
Neurol Res Pract; 2024 Jun; 6(1):32. PubMed ID: 38898536
[TBL] [Abstract][Full Text] [Related]
2. Inherited C-terminal TREX1 variants disrupt homology-directed repair to cause senescence and DNA damage phenotypes in Drosophila, mice, and humans.
Chauvin SD; Ando S; Holley JA; Sugie A; Zhao FR; Poddar S; Kato R; Miner CA; Nitta Y; Krishnamurthy SR; Saito R; Ning Y; Hatano Y; Kitahara S; Koide S; Stinson WA; Fu J; Surve N; Kumble L; Qian W; Polishchuk O; Andhey PS; Chiang C; Liu G; Colombeau L; Rodriguez R; Manel N; Kakita A; Artyomov MN; Schultz DC; Coates PT; Roberson EDO; Belkaid Y; Greenberg RA; Cherry S; Gack MU; Hardy T; Onodera O; Kato T; Miner JJ
Nat Commun; 2024 Jun; 15(1):4696. PubMed ID: 38824133
[TBL] [Abstract][Full Text] [Related]
3. Blood Biomarkers as Prognostic Indicators for Neurological Injury in COVID-19 Patients: A Systematic Review and Meta-Analysis.
Huang Z; Haile K; Gedefaw L; Lau BW; Jin L; Yip SP; Huang CL
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958721
[TBL] [Abstract][Full Text] [Related]
4. NFL and GFAP in (pre)symptomatic RVCL-S carriers: a monogenic cerebral small vessel disease.
Wilms AE; de Boer I; Pelzer N; In't Veld SGJG; Middelkoop HAM; Teunissen CE; Terwindt GM
J Neurol; 2024 Apr; ():. PubMed ID: 38581544
[TBL] [Abstract][Full Text] [Related]
5. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
[TBL] [Abstract][Full Text] [Related]
6. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
[TBL] [Abstract][Full Text] [Related]
8. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
9. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
[TBL] [Abstract][Full Text] [Related]
10. Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations (RVCL-S): An update on basic science and clinical perspectives.
Wilms AE; de Boer I; Terwindt GM
Cereb Circ Cogn Behav; 2022; 3():100046. PubMed ID: 36324396
[TBL] [Abstract][Full Text] [Related]
11. An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis.
Kaisey M; Lashgari G; Fert-Bober J; Ontaneda D; Solomon AJ; Sicotte NL
Curr Neurol Neurosci Rep; 2022 Oct; 22(10):675-688. PubMed ID: 36269540
[TBL] [Abstract][Full Text] [Related]
12. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study.
Verberk IMW; Laarhuis MB; van den Bosch KA; Ebenau JL; van Leeuwenstijn M; Prins ND; Scheltens P; Teunissen CE; van der Flier WM
Lancet Healthy Longev; 2021 Feb; 2(2):e87-e95. PubMed ID: 36098162
[TBL] [Abstract][Full Text] [Related]
13. Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease.
Huss A; Abdelhak A; Mayer B; Tumani H; Müller HP; Althaus K; Kassubek J; Otto M; Ludolph AC; Yilmazer-Hanke D; Neugebauer H
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009416
[TBL] [Abstract][Full Text] [Related]
14. Increased Neurofilament Light Chain Is Associated with Increased Risk of Long-Term Mortality in Cerebral Small Vessel Disease.
Jacob MA; Peters N; Cai M; Duering M; Engelter ST; Kuhle J; de Leeuw FE; Tuladhar AM
J Stroke; 2022 May; 24(2):296-299. PubMed ID: 35677985
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
